Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 324

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 324
---
 Office of Officers and Directors

The Iris Board consists of four members and is divided into two classes with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to Iris’s first annual meeting of stockholders) serving a two-year term. In accordance with Nasdaq corporate governance requirements, Iris is not required to hold an annual meeting until one year after its first fiscal year end following its listing on Nasdaq. The term of office of the first class of directors, consisting of Messrs. Peretz and Fernandez, will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Mr. Nanani, will expire at the second annual meeting of stockholders. Mr. Shah will serve until Iris’s next annual meeting of stockholders, when he is expected to stand for election by a vote of Iris’s stockholders. Iris’s officers are appointed by the Iris Board and serve at the discretion of the Iris Board, rather than for specific terms of office.

The Iris Board is authorized to appoint officers as it deems appropriate pursuant to the Iris Certificate of Incorporation.

<div align='center'>169</div>

TABLE OF CONTENTS

The Iris Board is authorized to appoint persons to the offices set forth in Iris’s Existing Bylaws. The Existing Bylaws provide that Iris’s officers consist of a Chairman of the Board, a Chief Executive Officer, a Chief Financial Officer, a Secretary and such other officers (including without limitation, a Chairman of the Board, Presidents, Vice Presidents, Assistant Secretaries and a Treasurer) as the Iris Board from time to time may determine.

#### Director Independence
Nasdaq listing standards require that a majority of the Iris Board be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. The Iris Board has determined that Messrs. Fernandez, Peretz and Shah are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules. Iris’s independent directors will have regularly scheduled meetings at which only independent directors are present.

#### Executive Officer and Director Compensation
None of our directors has received any cash compensation for services rendered to us. Subsequent to the closing of the IPO, Iris began paying a then-affiliate of the Sponsor, Tribe Capital